ESALF News and Press, Eisai Co Ltd From 12/14/23

"LEQEMBI Intravenous Infusion"Lecanemab) for the Treatment of Alzheimer's Disease to be Launched in Japan on December 20 TOKYO and CAMBRIDGE, Mass., Dec 14, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (...

2023-12-13 12:02:48 ET More on Biogen, Eisai, etc. Biogen: LEQEMBI's $10 Billion Potential Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript) Eisai Co., Ltd. 2023 Q2 - Results - Earnings Call Presentation Merck Keytruda combo fails ...

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma TOKYO, Dec 11, 2023 - (JCN Newswire) - Eisai ...

2023-12-08 07:23:58 ET More on Merck Merck & Co., Inc. (MRK) Management Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript) Merck Will Keep Your Retirement Income Healthy Merck: Not The Time To Be Adding Merck halts lung cancer trial fo...

Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand TOKYO, Nov 30, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Thai sales subsidiary Eisai (Thailand) Marketing Co., Ltd., (Eisai Thailand) has made an agreement to collaborate w...

2023-11-29 15:00:01 ET Summary Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; as a result, shares are down over 20% year-over-y...

Eisai to Present Latest Data on Perampanel at The 77th American Epilepsy Society (AES) Annual Meeting TOKYO, Nov 22, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will have a total of nine poster presentations, including the latest data on its in-house dis...

LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023 TOKYO and CAMBRIDGE, Mass., Nov 20, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) was awarde...

2023-11-08 07:40:46 ET More on Biogen Biogen - Revised Revenue Forecasting To 2030 - New CEO Faces Major Challenges Biogen Inc. (BIIB) Management presents at Decentralized Clinical Trials in Focus Conference (Transcript) Biogen Inc. (BIIB) Morgan Stanley 21st Annual ...

2023-11-07 16:25:19 ET Eisai Co Ltd (ESALF) Q2 2023 Earnings Conference Call November 07, 2023, 01:00 ET Company Participants Haruo Naito - CEO Lynn Kramer - VP & Chief Clinical Officer, Alzheimer's Disease and Brain Health Yasunobu Kai - Former Senior Group ...